Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1309 | Diagnostic test Covid-19 Wiki | 0.50 |
| drug839 | COVID-19 swap test PCR Wiki | 0.50 |
| drug2780 | Neurofeedback Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1305 | Diagnostic Test: serology test for COVID-19 Wiki | 0.50 |
| drug1793 | Goal Management Training (GMT) Wiki | 0.50 |
| drug1311 | Diagnostic test for detection of SARS-CoV-2 Wiki | 0.50 |
| drug1310 | Diagnostic test for SARS-Cov2 for patients and health staff Wiki | 0.50 |
| drug3364 | Prednisone Wiki | 0.19 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004827 | Epilepsy NIH | 0.35 |
| D060825 | Cognitive Dysfunction NIH | 0.33 |
| D012640 | Seizures NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001268 | Mental deterioration HPO | 0.33 |
| HP:0001250 | Seizure HPO | 0.22 |
| HP:0001297 | Stroke HPO | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 4 clinical trials
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThis study will evaluate the effect of a manualized treatment (Goal Management Training, or GMT) on the cognitive impairments associated with PTSD (Post-Traumatic Stress Disorder), as well as any impact on PTSD symptems themselves. Participants will be randomized to either GMT group treatment, or a wait list condition.
Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from baseline to post-treatment assessment Time: 9 weeksDescription: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from post-treatment to 3-month follow-up assessment Time: 12 weeksDescription: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Tower Test (part of Millisecond's online cognitive battery) from baseline to post-treatment assessment. Time: 9 weeksDescription: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Tower Test (part of Millisecond's online cognitive battery) from post-treatment to 3-month follow-up assessment. Time: 12 weeksDescription: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from baseline to post-treatment assessment Time: 9 weeksDescription: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from post-treatment to 3-month follow-up assessment Time: 12 weeksDescription: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from baseline to post-treatment assessment Time: 9 weeksDescription: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from post-treatment to 3-month follow-up assessment Time: 12 weeksThis is a single-center, blinded, placebo-controlled pilot RCT evaluating corticosteroids for the treatment of Community Acquired Pneumonia (CAP) that will enroll 100 adults hospitalized with community-acquired pneumonia. The primary goal is to assess the feasibility of proposed trial procedures for use in a subsequent phase III trial powered on 6-month cognitive outcome (MOCA-Blind score). Key outcomes are six-month cognitive and functional status, duration and severity of symptoms, and mortality.
Description: Feasibility will be defined as: (a) recruitment and successful protocol completion of 100 patients; (b) corticosteroids being well tolerated, as shown by similar severity and frequency of adverse events in the intervention and placebo groups; (c) successful completion of 6-month cognitive assessments by >80% of survivors; and (d) the primary cognitive outcome Montreal Cognitive Assessment-Blind (MOCA-Blind) numerically favoring the intervention group with the one-tailed upper 80% confidence interval of the difference in MOCA-Blind between the intervention and placebo groups containing the minimally-important clinical difference (2 points on the MOCA-Blind).
Measure: Feasibility as determined by the number of subjects who are successfully recruited and complete follow-up Time: 1.5 yearsDescription: This is a measure of global cognition based on the assessment of attention concentration, memory, language, conceptual thinking, calculations, and orientation. Scores range from 0 to 22 with higher scores indicating better cognition.
Measure: Global cognition as measured by the Montreal Cognitive Assessment-Blind (MOCA-Blind) Time: 6-monthsDescription: This is a 18-item scale to determine the presence and severity of pneumonia symptoms. Each item is graded on a 6-point Likert scale. Scores range from 0 to 90 with higher scores indicating more severe symptoms.
Measure: Severity of pneumonia symptoms as measured by the Community-Acquired Pneumonia Symptom (CAP-Sym) Questionnaire Time: 3-daysDescription: This is a 18-item scale to determine the presence and severity of pneumonia symptoms. Each item is graded on a 6-point Likert scale. Scores range from 0 to 90 with higher scores indicating more severe symptoms.
Measure: Severity of pneumonia symptoms as measured by the Community-Acquired Pneumonia Symptom (CAP-Sym) Questionnaire Time: 7-daysDescription: This is a 18-item scale to determine the presence and severity of pneumonia symptoms. Each item is graded on a 6-point Likert scale. Scores range from 0 to 90 with higher scores indicating more severe symptoms.
Measure: Severity of pneumonia symptoms as measured by the Community-Acquired Pneumonia Symptom (CAP-Sym) Questionnaire Time: 30-daysDescription: Characterizes quality of life and contains 5-dimensions ("5D") related to everyday living: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It asks patients to rate their current global health status from 0 (worst health you can imagine) to 100 (best health you can imagine). Scores range from -0.573 to 1.000 with higher scores indicating better quality of life.
Measure: Quality of life as measured by the EQ-5D-5L Time: 6-monthsDescription: Quantifies pre-illness basic ADLs such as bathing, dressing, toileting, transferring, continence, and feeding. Scores range from 0 to 20 with higher scores indicating better functioning.
Measure: Basic activities of daily living (ADL) as measured by the Barthel's Index Time: 6-monthsDescription: Quantifies pre-illness IADLs - ability to use the phone, shopping, food preparation, housekeeping, laundry, transportation, medication management, and finances. Scores range from 0 to 8 with higher scores indicating better functioning.
Measure: Instrumental ADL as measured by Lawton Instrumental Activities of Daily Living Scale (IADLs) Time: 6-monthsDescription: 9-item survey that characterizes the patient's baseline (prior to the critical illness) and current level of employment (full, partial, or not employed). Patients will be categorized as loss of employment or no loss of employment.
Measure: Employment status as characterized by the Outcomes After Critical Illness and Surgery (OACIS) Employment Status Questionnaire Time: 6-monthsDescription: Death during the index hospitalization will be recorded.
Measure: Vital status (dead / alive) Time: Baseline to hospital discharge, approximately 5 daysDescription: Death within 6-months will be recorded.
Measure: Vital status (dead / alive) Time: 6-monthsDescription: Intensive care unit admission at any point during the index hospitalization will be recorded.
Measure: Intensive care unit admission (yes/no) Time: Baseline to hospital discharge, approximately 5 daysDescription: Invasive mechanical ventilation is defined as new assisted positive pressure breathing through an endotracheal tube or tracheostomy for any duration. Noninvasive ventilation through a mask or nasal prongs does not satisfy the outcome of invasive mechanical ventilation.
Measure: Mechanical ventilation (yes/no) Time: Baseline to hospital discharge, approximately 5 daysDescription: defined as the administration of any of the following medications by continuous infusion for at least 1 hour during the index hospitalization: norepinephrine, epinephrine, dopamine, phenylephrine or vasopressin.
Measure: Vasopressor use (yes/no) Time: Baseline to hospital discharge, approximately 5 daysDescription: Pleural drainage is defined as removal of fluid from the pleural space by any procedure at the bedside or in the operating room during the index hospitalization; procedures such as thoracentesis and video-assisted thorascopic surgery (VATS) may be used to drain pleural fluid.
Measure: Pleural drainage (yes/no) Time: Baseline to hospital discharge, approximately 5 daysDescription: Duration of hospitalization (presentation to hospital discharge) will be recorded.
Measure: Hospital length of stay in (days) Time: Baseline to hospital discharge, approximately 5 daysThis study is an effectiveness trial investigating neurofeedback (NFB) in adults with PTSD (Post-Traumatic Stress Disorder). Participants will be randomly assigned to one of two treatment conditions - i) NFB, or ii) wait list. Due to the coronavirus pandemic, our study will, primarily, take place online (i.e., online assessment and treatment, with option of in-person fMRI, or functional magnetic resonance imaging, scans). NFB sessions will be conducted from home, with videoconferenced supervision by research staff. After study completion, individuals in the wait list condition will be offered the same NFB treatment.
Description: Gold standard, clinician-administered PTSD assessment tool; min. score=0, max.=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from baseline to post-treatment assessment. Time: 19 weeksDescription: Gold standard, clinician-administered PTSD assessment tool; min. score=0, max.=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from post-treatment to 3-month follow-up assessment. Time: 12 weeksDescription: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from baseline to post-treatment assessment Time: 19 weeksDescription: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from post-treatment to 3-month follow-up assessment Time: 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports